The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has given the green light for the use of delgocitinib (Anzupgo) to treat adults suffering from moderate to severe chronic hand eczema when topical corticosteroids prove ineffective or unsuitable.
Chronic hand eczema is characterized as a persistent inflammatory skin disorder, often leading to symptoms like itching and discomfort.
Obtained via the International Recognition Procedure (IRP) Pathway B, the marketing approval was issued to Leo Pharma AS within a swift 59-day period on November 29, 2024.
Anzupgo, containing the active ingredient delgocitinib, is categorized under Janus kinase inhibitors, a class of medicines.
Delgocitinib operates by targeting and inhibiting the activity of four specific Janus kinase enzymes to mitigate inflammation and immune reactions responsible for hand eczema. This action not only eases skin inflammation, itching, and discomfort but also enhances the capability to engage in everyday tasks, improving overall life quality.
As is customary with any medicinal product, the MHRA will continue to rigorously monitor the safety and efficacy of delgocitinib. Patients experiencing any adverse effects are urged to seek consultation with their healthcare provider and report any side effects directly to the Yellow Card scheme, accessible online at https://yellowcard.mhra.gov.uk/ or through apps available on the Google Play or Apple App Store.
The MHRA, responsible for the oversight of all medications and medical devices in the UK, ensures their efficacy and safety. Its foundation rests on solid, evidence-based evaluations to establish that advantages outweigh potential risks.
As an executive agency under the Department of Health and Social Care, the MHRA is committed to maintaining and safeguarding public health by regulating medicinal products and devices effectively.